Clinical Trials Directory

Trials / Completed

CompletedNCT02858388

Sinuclean Nebules 45 for Treatment of Pediatric Exudative Otitis Media

Safety and Efficacy of Sinuclean Nebules 45 (Class 1 Medical Device) in the Treatment of Pediatric Exudative Otitis Media, Randomized, Double Blind, Comparative, Parallel Study

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
70 (actual)
Sponsor
Galsor S.r.l. · Industry
Sex
All
Age
3 Years – 10 Years
Healthy volunteers
Not accepted

Summary

The goal of the study is to investigate if the active agent of Sinuclean Nebules is efficacious in the treatment of pediatric exudative otitis media, comparing with saline. Sinuclean Nebules is a solution of cucurbitacins B,D,I,E (glycosylated triterpenes) 45 mcg, extracted from Ecballium Elaterium.

Detailed description

Eligible pediatric subjects with diagnosis of mono or bi-lateral exudative otitis media (obtained with otorhinolaryngologic endoscopic examination, tympanogram and tonal audiometry), are randomized to treatment with Sinuclean Nebules 45 or saline. Treatment is administered by trained caregiver with nebulizer (Rinowash Nasal Shower): one nebulization/nostril/day for two cycles of 10 consecutive days. Cycles are interrupted by a period of 7 days. Visits 1 Baseline T0: confirmation of eligibility, randomization, training of caregiver, dispensation of blinded therapy for two cycles, delivery of the clinical diary. Visit 2 after 10 days of therapy + 7 days of interval: phone call to check for adverse events, therapy adherence, concomitant diseases and treatments, and to prescribe second cycle of therapy. Visit 3 End of Study: assessment of the exudative otitis media with otorhinolaryngologic endoscopic examination, tympanogram tonal audiometry, verification of the subject's clinical diary.

Conditions

Interventions

TypeNameDescription
DEVICESinuclean Nebules 45Nebulization of solution
OTHERSaline solutionNebulization of solution

Timeline

Start date
2015-01-01
Primary completion
2015-09-01
Completion
2015-12-01
First posted
2016-08-08
Last updated
2016-08-08

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT02858388. Inclusion in this directory is not an endorsement.